Hostname: page-component-7b7567c8c-tnkh4 Total loading time: 0 Render date: 2026-11-16T23:54:57.369Z Has data issue: false hasContentIssue false

Don't disregard the essential distinction between PUFA species

Published online by Cambridge University Press:  17 June 2011

Christopher E. Ramsden
Affiliation:
Section on Nutritional Neurosciences, Laboratory of Membrane Biochemistry and Biophysics, National Institute on Alcohol Abuse, National Institutes of Health, Bethesda, MD, USA, email chris.ramsden@nih.gov
Joseph R. Hibbeln
Affiliation:
Section on Nutritional Neurosciences, Laboratory of Membrane Biochemistry and Biophysics, National Institute on Alcohol Abuse, National Institutes of Health, Bethesda, MD, USA, email chris.ramsden@nih.gov
Sharon F. Majchrzak-Hong
Affiliation:
Section on Nutritional Neurosciences, Laboratory of Membrane Biochemistry and Biophysics, National Institute on Alcohol Abuse, National Institutes of Health, Bethesda, MD, USA, email chris.ramsden@nih.gov
John M. Davis
Affiliation:
Department of Psychiatry, School of Medicine, University of Illinois, Chicago, IL, USA
Rights & Permissions [Opens in a new window]

Abstract

Information

Type
Letter to the editor
Copyright
Copyright © The Authors 2011
Figure 0

Table 1Pooled analyses cited as the primary evidence base for CHD benefits of n-6 linoleic acid (LA): no clear distinction made between n-3 and n-6 PUFA species(adapted with permission from Ramsden et al.(11))*

Figure 1

Table 2Limited capacity of food-frequency questionnaires in the Nurses' Health Study (NHS) to disentangle respective intakes of n-3 α-linolenic acid (ALA) and n-6 linoleic acid (LA)(adapted with permission from Ramsden et al.(11))*

Figure 2

Fig. 1No indication of benefit, and a signal toward harm, in non-fatal myocardial infarction (MI)+CHD death (a) and in CHD death (b) shown by n-6 specific PUFA interventions. PUFA replaced a combination of trans-fatty acids and SFA in each randomised controlled trial (RCT). ‘A’ indicates mixed n-3/n-6 PUFA RCT datasets increasing n-3 EPA+DHA and n-6 linoleic acid (LA); ‘B’ indicates mixed n-3/n-6 PUFA RCT datasets increasing n-3 α-linolenic acid (ALA) and n-6 LA; ‘C’ indicates n-6 specific PUFA RCT datasets selectively increasing n-6 LA. Each of two RCT datasets increasing LA+EPA and DHA showed a trend toward benefit; pooled analysis showed significant reduction in non-fatal MI+CHD death (risk ratio (RR) 0·74 (95 % CI 0·57, 0·97); P = 0·03), and trends toward reduction in CHD death (RR 0·72 (95 % CI 0·50, 1·05); P = 0·09) and death from all causes (RR 0·73 (95 % CI 0·52, 1·04); P = 0·08) (Fig. 2). Each of the two RCT datasets increasing LA+ALA, and their pooled analysis showed a trend toward reduced risk of non-fatal MI+CHD death (RR 0·81 (95 % CI 0·64, 1·02); P = 0·07), and signals toward reduction in death from CHD (RR 0·87 (95 % CI 0·64, 1·19); P = 0·39) and all-cause mortality (RR 0·96 (95 % CI 0·83, 1·12); P = 0·62) (Fig. 2). The four individual n-6 specific PUFA RCT datasets, and pooled analysis of all four datasets showed a relatively consistent trend toward increased risk of non-fatal MI+CHD death (RR 1·23 (95 % CI 0·94, 1·61); P = 0·13), death from CHD (RR 1·28 (95 % CI 0·96, 1·70); P = 0·09), and of death from all causes (RR 1·16 (95 % CI 0·95, 1·42); P = 0·15) (Fig. 2). The structure of these RCT data suggest that CHD benefits previously attributed to n-6 PUFA or total PUFA may have been due to substantial increases in n-3 PUFA, particularly n-3 EPA+DHA, and that the accompanying increases in n-6 LA attenuated these benefits. Calculated RR, 95 % CI and P values include data from all eight datasets included in the primary analysis. As explained in the text, the Sydney Diet Heart Study (SDHS) reported a 49 % increased risk of CHD with an n-6 specific intervention (RR 1·49 (95 % CI 0·95, 2·34); P = 0·08). Only total deaths were reported for each group; however, 91 % of these total deaths were attributed to CHD. Therefore, the pooled analysis of only three of the four n-6 specific RCT datasets without the SDHS underestimates the potential harm of n-6 PUFA. The CHD event data in Fig. 1 model the assumption that 91 % of total deaths in each group were due to CHD, allowing for a more accurate estimation of the CHD effects of replacing trans- and saturated fats with n-6 LA because it includes all four n-6 specific PUFA datasets. Based on reported SDHS data for total deaths and CHD death, the lowest possible pooled increase in risk of CHD death from the four n-6 specific PUFA datasets was +21 % (RR 1·21 (95 % CI 0·91, 1·60); P = 0·20); the highest possible increase was +40 % (RR 1·40 (95 % CI 0·97, 2·02); P = 0·07).

Figure 3

Fig. 2No indication of benefit, and a signal toward harm, in deaths from all causes shown by n-6 specific PUFA interventions. PUFA replaced a combination of trans-fatty acids and SFA in each randomised controlled trial (RCT). ‘A’ indicates mixed n-3/n-6 PUFA RCT datasets increasing n-3 EPA + DHA and n-6 linoleic acid (LA); ‘B’ indicates mixed n-3/n-6 PUFA RCT datasets increasing n-3 α-linolenic acid (ALA) and n-6 LA; ‘C’ indicates n-6 specific PUFA RCT datasets selectively increasing n-6 LA. All RCT reported total death. RCT data follow the same pattern as observed for CHD events and CHD deaths. Pooled analysis of two datasets increasing LA +EPA and DHA showed a trend toward reduced risk of death (risk ratio (RR) 0·73 (95 % CI 0·52, 1·04); P = 0·08); two datasets increasing LA+ALA showed no difference (RR 0·96 (95 % CI 0·83, 1·12); P = 0·62); four datasets selectively increasing n-6 LA in place of trans- and saturated fats showed a signal toward increased risk of death (RR 1·16 (95 % CI 0·95, 1·42); P = 0·15).